SUPN:NASDAQSupernus Pharmaceuticals, Inc. Analysis

Supernus Pharmaceuticals is posting robust top‑line momentum with 21.5% YoY revenue growth and an impressive 89.6% gross margin, while its cash pile of $308 M comfortably dwarfs its $40.9 M debt load. Forward EPS of $4.22 and a forward P/E of 11.3 contrast sharply with a trailing loss, indicating a potential earnings turnaround. The DCF‑derived fair value of $61.0 suggests roughly a 31% upside from the current $47.85 price, and analysts are already rating the stock a strong buy with median price targets near $64. Recent material news includes a $350 M acquisition of Navitor’s SPN‑820 asset, expanding the pipeline, and an upcoming Q1‑2026 earnings release that could confirm the earnings recovery.
Technically, the stock sits just above its $47.17 support level and below the 20‑day SMA of $49.96, with a bearish MACD histogram and an RSI of 38 indicating modest downside pressure. Volatility is elevated at over 30% on a 30‑day basis, but beta of 0.80 points to slightly lower market sensitivity. Stable trading volume and a neutral trend suggest no immediate liquidity stress, though short‑term caution is warranted pending the earnings announcement.